Loading...

We've got a brand new version of Simply Wall St! Try it out

FSD Pharma

CNSX:HUGE
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HUGE
CNSX
CA$153M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • FSD Pharma has significant price volatility in the past 3 months.
HUGE Share Price and Events
7 Day Returns
0%
CNSX:HUGE
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-88.8%
CNSX:HUGE
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
HUGE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
FSD Pharma (HUGE) 0% -9.1% -31% -88.8% - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • HUGE underperformed the Pharmaceuticals industry which returned -45.8% over the past year.
  • HUGE underperformed the Market in Canada which returned -0.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

HUGE Value

 Is FSD Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for FSD Pharma. This is due to cash flow or dividend data being unavailable. The share price is CA$0.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for FSD Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are FSD Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:HUGE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.02
CNSX:HUGE Share Price ** CNSX (2019-09-19) in CAD CA$0.1
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of FSD Pharma.

CNSX:HUGE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:HUGE Share Price ÷ EPS (both in CAD)

= 0.1 ÷ -0.02

-4.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FSD Pharma is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • FSD Pharma is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does FSD Pharma's expected growth come at a high price?
Raw Data
CNSX:HUGE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for FSD Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on FSD Pharma's assets?
Raw Data
CNSX:HUGE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.04
CNSX:HUGE Share Price * CNSX (2019-09-19) in CAD CA$0.1
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:HUGE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:HUGE Share Price ÷ Book Value per Share (both in CAD)

= 0.1 ÷ 0.04

2.26x

* Primary Listing of FSD Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FSD Pharma is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess FSD Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. FSD Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HUGE Future Performance

 How is FSD Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FSD Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is FSD Pharma expected to grow at an attractive rate?
  • Unable to compare FSD Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare FSD Pharma's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare FSD Pharma's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:HUGE Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:HUGE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:HUGE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -26 -34
2019-03-31 0 -21 -22
2018-12-31 0 -18 -23
2018-09-30 0 1 -2
2018-06-30 0 -5 -9
2018-03-31 0 -2 -5
2017-12-31 0 0 -4
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if FSD Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if FSD Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:HUGE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from FSD Pharma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:HUGE Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.02
2019-03-31 -0.02
2018-12-31 -0.02
2018-09-30 0.00
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 0.00
2016-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if FSD Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of HUGE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. FSD Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. FSD Pharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess FSD Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
FSD Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HUGE Past Performance

  How has FSD Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare FSD Pharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • FSD Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare FSD Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare FSD Pharma's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
FSD Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from FSD Pharma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:HUGE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.06 -33.58 26.04
2019-03-31 0.07 -21.50 16.74
2018-12-31 0.09 -22.71 16.66
2018-09-30 0.11 -2.21 8.73
2018-06-30 0.10 -9.13 8.98
2018-03-31 0.07 -5.36 5.56
2017-12-31 0.03 -3.52 3.55
2016-12-31 -0.18 0.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if FSD Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if FSD Pharma has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if FSD Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess FSD Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
FSD Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HUGE Health

 How is FSD Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up FSD Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • FSD Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • FSD Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of FSD Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from FSD Pharma Company Filings, last reported 2 months ago.

CNSX:HUGE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 66.95 1.92 9.84
2019-03-31 49.50 0.00 17.11
2018-12-31 51.03 0.00 21.13
2018-09-30 66.29 0.00 33.79
2018-06-30 52.49 0.00 31.70
2018-03-31 13.14 0.00 3.09
2017-12-31 12.41 0.00 4.74
2016-12-31 0.42 0.01 0.03
  • FSD Pharma's level of debt (2.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if FSD Pharma's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • FSD Pharma has less than a year of cash runway based on current free cash flow.
  • FSD Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 72.3% each year.
X
Financial health checks
We assess FSD Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. FSD Pharma has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HUGE Dividends

 What is FSD Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from FSD Pharma dividends.
If you bought CA$2,000 of FSD Pharma shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate FSD Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate FSD Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:HUGE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as FSD Pharma has not reported any payouts.
  • Unable to verify if FSD Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of FSD Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as FSD Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess FSD Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can FSD Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. FSD Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HUGE Management

 What is the CEO of FSD Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Raza Bokhari
COMPENSATION CA$11
AGE 51
TENURE AS CEO 0.6 years
CEO Bio

Dr. Raza Bokhari, M.D., MBA is the Managing Partner at RBx Capital LP. Dr. Bokhari has been Executive Co-Chairman of FSD Pharma Inc. since October 2018 and serves as its Chief Executive Officer since May 2019. Dr. Bokhari serves as the Chairman of Parkway Clinical Laboratories Inc. and served as its CEO until December 2018. He was an Interim Chief Executive Officer of FSD Pharma Inc. since February 7, 2019 until May 2019. Dr. Bokhari served as Interim Chief Executive Officer of FSD Pharma Inc. from October 2018 to November 26, 2018. Dr. Bokhari has significant experience of working with life science and healthcare services companies in the US. Dr. Bokhari was the President and Chief Executive Officer at Lakewood Pathology Associates from 2001 until 2007. He served as an Independent Director at Akers Biosciences, Inc. from November 11, 2015 to August 10, 2017. He served as a Director of PLUS Diagnostics, Inc and served as Chief Executive officer since May 2007 and President since April 2008 respectively. He has been Director of FSD Pharma Inc. since July 17, 2018. He has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College and an Executive MBA from Temple University, Fox School of Business & Management. He is Recipient of Philadelphia Business Journal's "40 under 40" award, physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies. He has a vast knowledge base of developing creative concepts, implementing programs and forming strategic alliances.

CEO Compensation
  • Insufficient data for Raza to compare compensation growth.
  • Raza's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the FSD Pharma management team in years:

0.6
Average Tenure
  • The average tenure for the FSD Pharma management team is less than 2 years, this suggests a new team.
Management Team

Anthony Durkacz

TITLE
Founder & Co-Chairman
AGE
43

Raza Bokhari

TITLE
Executive Co-Chairman & CEO
COMPENSATION
CA$11
AGE
51
TENURE
0.6 yrs

Zeeshan Saeed

TITLE
Founder
COMPENSATION
CA$1M
TENURE
0.9 yrs

Don Carroll

TITLE
Interim Chief Financial Officer
COMPENSATION
CA$244K
TENURE
1.2 yrs

Sandy Huard

TITLE
Head of Communications & Investor Relation

Ed Brennan

TITLE
President of Biosciences Division
TENURE
0.3 yrs

Zak Dutton

TITLE
Chief Executive Officer of BioSciences Division
TENURE
0.7 yrs

Sara May

TITLE
President of FV Pharma
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the FSD Pharma board of directors in years:

0.6
Average Tenure
57.5
Average Age
  • The average tenure for the FSD Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Anthony Durkacz

TITLE
Founder & Co-Chairman
AGE
43
TENURE
0.9 yrs

Raza Bokhari

TITLE
Executive Co-Chairman & CEO
COMPENSATION
CA$11
AGE
51
TENURE
0.9 yrs

Zeeshan Saeed

TITLE
Founder
COMPENSATION
CA$1M
TENURE
1.3 yrs

Gerry Goldberg

TITLE
Independent Director
COMPENSATION
CA$33K
AGE
75
TENURE
1.3 yrs

Larry Kaiser

TITLE
Chairman of Scientific Advisory Board
TENURE
0.2 yrs

David Urban

TITLE
Independent Director
COMPENSATION
CA$7K
AGE
64
TENURE
0.8 yrs

Charles Pollack

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

Daniele Piomelli

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs

Ryan Vandrey

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs

David Casarett

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
19. Oct 18 Sell Thomas Fairfull Individual 17. Oct 18 17. Oct 18 -13,227,581 CA$0.64 CA$-8,465,652
09. Oct 18 Sell Donal Carroll Individual 08. Oct 18 09. Oct 18 -565,000 CA$0.76 CA$-420,351
23. Sep 18 Sell Donal Carroll Individual 20. Sep 18 21. Sep 18 -700,000 CA$0.84 CA$-585,912
X
Management checks
We assess FSD Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. FSD Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HUGE News

Simply Wall St News

How Many Insiders Sold FSD Pharma Inc. (CNSX:HUGE) Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … In the last twelve months, the biggest single sale by an insider was when Thomas Fairfull sold CA$8.5m worth of shares at a price of CA$0.64 per share. … It is certainly not great to see that insiders have sold shares in the company

Simply Wall St -

How Much Of FSD Pharma Inc. (CNSX:HUGE) Do Insiders Own?

So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … With a market capitalization of CA$426m, FSD Pharma is a small cap stock, so it might not be well known by many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Who Are The Largest Shareholders In FSD Pharma Inc (CNSX:HUGE)?

In this analysis, my focus will be on developing a perspective on FSD Pharma Inc’s (CNSX:HUGE) latest ownership structure, a less discussed, but important factor. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.

Simply Wall St -

What You Must Know About FSD Pharma Inc's (CNSX:HUGE) 2.11% ROE

and want a simplistic look at the return on FSD Pharma Inc (CNSX:HUGE) stock. … FSD Pharma Inc (CNSX:HUGE) delivered a less impressive 2.11% ROE over the past year, compared to the 5.30% return generated by its industry. … Today I will look at how components such as financial leverage can influence ROE which may impact the sustainability of HUGE's returns.

Simply Wall St -

HUGE Company Info

Description

FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for various central nervous system disorders, including chronic pain, fibromyalgia, and irritable bowel syndrome. FSD Pharma Inc. has a strategic alliance agreement with SciCann Therapeutics Inc. for the production and distribution of cannabinoid-based, patent pending, and indication-specific products. The company is headquartered in Cobourg, Canada.

Details
Name: FSD Pharma Inc.
HUGE
Exchange: CNSX
Founded:
CA$152,770,183
1,527,701,831
Website: http://fsdpharma.com
Address: FSD Pharma Inc.
520 William Street,
Cobourg,
Ontario, K9A 3A5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX HUGE Class B Subordinate Voting Shares Canadian National Stock Exchange CA CAD 29. May 2018
OTCPK FSDD.F Class B Subordinate Voting Shares Pink Sheets LLC US USD 29. May 2018
DB 0K9 Class B Subordinate Voting Shares Deutsche Boerse AG DE EUR 29. May 2018
Number of employees
Current staff
Staff numbers
19
FSD Pharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:26
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.